An observational study in Diabetes Mellitus, sponsored by Gulhane School of Medicine. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.
Sponsored by Gulhane School of Medicine · Observational
This study evaluates the metabolic control status, cardiovascular risk and frequency of comorbidities in diabetic patients followed in tertiary treatment centers in Turkey.
Diabetes mellitus is one of the most common chronic diseases worldwide.The prevalence of diabetes is increased significantly in Türkiye, from 7.2 % in 2002 to 13.7% in 2012. This increasing prevalence leads to serious public health problems and a significant economic burden. Many important diseases such as hypertension and dyslipidemia accompany the picture in diabetic patients. The optimal treatment of diabetes and prevention of diabetic complications, especially the cardiovascular outcomes, is utmost important. Although achieving glycemic targets in patients with diabetes is of great importance, blood glucose is not the only predictor of cardiovascular outcome in diabetes. Optimization of other metabolic parameters such as lipids, arterial blood pressure (ABP), and body weight as well as a healthy lifestyle are utmost important.
Common problems in diabetic patients, such as sleep disorders and sexual dysfunction, affect glycemia regulation in these patients.There is little data on the frequency of these diseases in diabetic patients in Türkiye.
In the TEMD-1 study conducted in 2017, the rates of diabetic patients achieving metabolic goals and the factors affecting these rates were revealed in Turkish patients with diabetes. The findings obtained in the current study will be compared with the findings in 2017, and in addition, the frequency of comorbidities such as sleep disorder, sexual dysfunction, and depression will be tried to be revealed.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 5,707 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Gulhane School of Medicine is the lead sponsor of 66 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with type 1 or type 2 diabetes who were under follow-up in the same tertiary endocrine unit for at least a year were enrolled.
Exclusion Criteria:
Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
Other: There is no intervention.
There is no intervention.
Glycemia control status of Turkish adult patients with diabetes mellitus
Glycemia control will be defined as good control if the mean HbA1c level of patients \< 7% or poor control if the mean HbA1c level of patient between 7% and 9% and very poor control if the mean HbA1c level of patient \> 9%
Time frame: 7 days
Blood pressure control status of Turkish adult patients with diabetes mellitus
Home blood pressure \<135/85 mmHg or office blood pressure \<140/90 mmHg will be defined as under control.
Time frame: 7 days
Lipid control status of Turkish adult patients with diabetes mellitus.
Triglyceride \< 150 mg/dl, LDL-C \<55 mg/dl, \<70 mg/dl and \< 100 mg/dl according to the cardiovascular risk status, HDL-C \> 40 mg/dl for men, and HDL-C \> 50 mg/dl for women will be defined as under control.
Time frame: 7 days
Weight control status of Turkish adult patients with diabetes mellitus.
Body mass index \< 30 kg/m2 will be defined as under control. Weight and height will be combined to report body mass index in kg/m2.
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gulhane School of Medicine